KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

被引：0
|
作者：
Schmid, P. [1 ]
Cortes, J. [2 ,3 ,4 ]
Dent, R. [5 ]
Pusztai, L. [6 ]
McArthur, H. L. [7 ]
Kuemmel, S. [8 ]
Bergh, J. [9 ,10 ]
Denkert, C. [11 ]
Park, Y. H. [12 ]
Hui, R. [13 ,14 ]
Harbeck, N. [15 ]
Takahashi, M. [16 ]
Foukakis, T. [9 ,10 ]
Fasching, P. A. [17 ]
Cardoso, F. [18 ]
Jia, L. [19 ]
Karantza, V. [20 ]
Zhao, J. [21 ]
Aktan, G. [20 ]
O'Shaughnessy, J. [22 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[2] IOB Inst Oncol, Quironsalud Grp, Oncol Dept, Madrid, Spain
[3] IOB Inst Oncol, Quironsalud Grp, Oncol Dept, Barcelona, Spain
[4] Vall dHebron Intitute Oncol VHIO, Barcelona, Spain
[5] Univ Toronto, Toronto, ON, Canada
[6] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
[7] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
[8] Kliniken Essen Mitte Evang, Breast Unit, Essen, Germany
[9] Karolinska Inst, Dept Oncol Pathol, Solna, Sweden
[10] Karolinska Univ Hosp, Breast Canc Ctr, Canc Theme, Solna, Sweden
[11] Philipps Univ Marburg, Inst Pathol, Marburg, Germany
[12] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Hematol Oncol, Seoul, South Korea
[13] Westmead Hosp, Dept Med Oncol, Sydney, NSW, Australia
[14] Univ Sydney, Sydney, NSW, Australia
[15] Univ Munich LMU, Breast Ctr, Dept Gynecol & Obstet, Munich, Germany
[16] NKO Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan
[17] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Gynecol & Obstet, Erlangen, Germany
[18] Champalimaud Fdn, Breast Unit, Canc Ctr, Lisbon, Portugal
[19] Merck & Co Inc, Biostat, Kenilworth, NJ USA
[20] Merck & Co Inc, Dept Oncol, Kenilworth, NJ USA
[21] Merck & Co Inc, Biostat, N Wales, PA USA
[22] Baylor Univ, Med Ctr, Breast Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA8_PR
引用
收藏
页码：853 / 854
页数：2
相关论文
共 50 条
  • [21] KEYNOTE-585: Phase 3 study of chemotherapy (chemo) plus pembrolizumab (pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Tabernero, Josep
    Ilson, David H.
    Hyung, Woo Jin
    Strong, Vivian E.
    Goetze, Thorsten Oliver
    Yoshikawa, Takaki
    Tang, Laura H.
    Hwang, Peggy May Tan
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
    Schmid, P.
    Cortes, J.
    Dent, R.
    Pusztai, L.
    McArthur, H.
    Kummel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Untch, M.
    Fasching, P. A.
    Cardoso, F.
    Ding, Y.
    Tryfonidis, K.
    Aktan, G.
    Karantza, V.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1198 - 1200
  • [23] KEYNOTE-522 study of neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses
    Schmid, Peter
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    McArthur, Heather
    Kummel, Sherko
    Bergh, Jonas
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Andersen, Jay
    Patt, Debra
    Danso, Michael
    Ferreira, Marta
    Mouret-Reynier, Marie-Ange
    Im, Seock-Ah
    Ahn, Jin-Hee
    Gion, Maria
    Baron-Hay, Sally
    Boileau, Jean-Francois
    Zhu, Yalin
    Pan, Wilbur
    Tryfonidis, Konstantinos
    Karantza, Vassiliki
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2022, 82 (04)
  • [24] Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for highrisk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study
    Schmid, P.
    Cortes, J.
    Dent, R. A.
    McArthur, H. L.
    Pusztai, L.
    Kummel, S.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Im, S-A.
    Untch, M.
    Fasching, P. A.
    Cardoso, F.
    Zhao, J.
    Zhou, X.
    Tryfonidis, K. E.
    Aktan, G.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2024, 35 : 1204 - 1205
  • [25] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro) plus chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Cortes, J.
    ark, Y. H.
    Munoz-Couselo, E.
    Kim, S-B
    Sohn, J.
    Im, S-A
    Holgado, E.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Wang, A.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [26] Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
    Schmid, Peter
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Foukakis, Theodoros
    Mouret-Reynier, Marie-Ange
    Ferreira, Marta
    Im, Seock-Ah
    Cardoso, Fatima
    Ding, Yu
    Pan, Wilbur
    Tryfonidis, Konstantinos
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [27] Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
    Schmid, P.
    Cortes, J.
    Dent, R. A.
    Pusztai, L.
    McArthur, H. L.
    Kummel, S.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Reynier, M. A. Mouret
    Ferreira, M. I. R.
    Im, S. A.
    Cardoso, F.
    Ding, Y.
    Pan, W.
    Tryfonidis, K. E.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1257 - S1257
  • [28] KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC)
    Schmid, P.
    Park, Y. H.
    Munoz-Couselo, E.
    Kim, S-B
    Sohn, J.
    Im, S-A
    Holgado, E.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Yin, L.
    Ding, Y.
    Tryfonidis, K.
    Cortes, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
    Dent, Rebecca
    Cortes, Javier
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Bergh, Jonas
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Haiderali, Amin
    Jia, Liyi
    Nguyen, Allison Martin
    Pan, Wilbur
    O'Shaughnessy, Joyce
    Schmid, Peter
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (10): : 1654 - 1663
  • [30] KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).
    Rugo, Hope S.
    Llombart-Cussac, Antonio
    Andre, Fabrice
    Robson, Mark E.
    Saji, Shigehira
    Harbeck, Nadia
    Schmid, Peter
    Cescon, David W.
    Ahn, Jin Seok
    Nanda, Rita
    Bardia, Aditya
    Fan, Li
    Mejia, Jaime Alberto
    Karantza, Vassiliki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345